Estimation of some physiological biomarkers in hyperlipidemic Patient men in Al- Zubair General Hospital / Basrah province, Iraq

Hyperlipidemia is a serious public health problem that affects many People in the world's, and it has been classified as one of the five causes of death in the world. As indicated by the World Health Organization (WHO), in 2030, hyperlipidemia incidence may increase the cardiovascular diseases to approximately 23.6 million people in the world. The aim of the study: Estimation of some physiological biomarkers levels in the serum of hyperlipidemic patients to predict atherosclerotic and cardiovascular disease. In addition to determine the effect of smoking and body mass index on the levels of biomarkers in hyperlipidemic patients.Patients and Methods: The study was conducted on patients who visited the internal consultation unit at Al-Zubair Hospital of Basra Health Directorate during the period from October 2020 to February 2021. The study was applied to a random sample of 60 hyperlipidemia men and 21 volunteers as a health group for comparison, whose ages range from 20-60 years. RESULTS: The results showed a significant increase in the levels of both Vascular cell adhesion molecule-1 (VCAM-1) and Malondialdehyde (MDA) and a significant decrease in the level of Glutathione Peroxidase-1 (GPX-1) in smoking patients compared to the healthy group. While Oxidized low-density lipoprotein (ox-LDL) did not show a significant difference between the patients smokers and healthy group. While the results showed a significant increase in the levels of VCAM-1, ox-LDL and MDA and a significant decrease in the level of GPX-1 among patients in the overweight and obese groups compared with the healthy group. The results did not show significant differences between the patients of the normal weight category and the healthy group.